Bedlack Richard S, Vaughan Timothy, Wicks Paul, Heywood Jamie, Sinani Ervin, Selsov Roger, Macklin Eric A, Schoenfeld David, Cudkowicz Merit, Sherman Alex
From the Department of Neurology (R.S.B.), Duke University and Durham VA Medical Center, Durham, NC; PatientsLikeMe (T.V., P.W., J.H.), Cambridge, MA; Massachusetts General Hospital (E.S., R.S., E.A.M., D.S., M.C., A.S.), Boston; and Harvard Medical School (E.A.M.), Boston, MA.
Neurology. 2016 Mar 1;86(9):808-12. doi: 10.1212/WNL.0000000000002251. Epub 2015 Dec 9.
To determine the frequency of amyotrophic lateral sclerosis (ALS) plateaus and reversals in the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database.
We analyzed Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) and ALSFRS-revised (ALSFRS-R) data from PRO-ACT participants. The frequencies of participants experiencing plateaus (periods where scores did not change) were calculated over 6-, 12-, and 18-month epochs. The percentage of participants ever experiencing reversals (periods where scores improved) of different lengths were also calculated and plotted.
Over 6 months, 25% of 3,132 participants did not decline. Over 12 months, 16% of 2,105 participants did not decline. Over 18 months, 7% of 1,218 participants did not decline. Small ALS reversals were also common, especially over shorter follow-up intervals; 14% of 1,343 participants had a 180-day interval where their ALSFRS-R slope was greater than zero. Fewer than 1% of participants ever experienced improvements of 4 or more ALSFRS-R points lasting at least 12 months.
ALS plateaus and small reversals are common, especially over brief intervals. In light of these data, stable disease, especially for a short period of time, should not be interpreted as an ALS treatment effect. Large sustained ALS reversals, on the other hand, are rare, potentially important, and warrant further study.
确定汇总资源开放获取肌萎缩侧索硬化症(ALS)临床试验(PRO-ACT)数据库中肌萎缩侧索硬化症(ALS)病情平稳期和病情逆转的频率。
我们分析了PRO-ACT参与者的肌萎缩侧索硬化症功能评定量表(ALSFRS)和修订版ALSFRS(ALSFRS-R)数据。计算了在6个月、12个月和18个月时间段内经历病情平稳期(评分未变化的时期)的参与者频率。还计算并绘制了经历不同时长病情逆转(评分改善的时期)的参与者百分比。
在6个月期间,3132名参与者中有25%病情未恶化。在12个月期间,2105名参与者中有16%病情未恶化。在18个月期间,1218名参与者中有7%病情未恶化。小幅度的ALS病情逆转也很常见,尤其是在较短的随访间隔期;1343名参与者中有14%在180天的时间段内其ALSFRS-R斜率大于零。经历ALSFRS-R评分提高4分或更多且持续至少12个月的参与者不到1%。
ALS病情平稳期和小幅度病情逆转很常见,尤其是在短时间内。鉴于这些数据,病情稳定,尤其是短时间内的稳定,不应被解读为ALS治疗效果。另一方面,大幅度且持续的ALS病情逆转很少见,可能很重要,值得进一步研究。